American Association of Diabetes Educators

Login
Home Page
Your Personalized Guide
to AADE Resources
AADE GPS
My Profile
My Memberships
My Purchases
MY AADE NETWORK
My Open Invoices
Join Online
Online Store
Events
Make a Donation
Access My Learning
Access AADE7 System
Find a Diabetes Educator
Apply For/Manage My DEAP Application
Reducing Cardiovascular Risk in T2DM with SGLT2 Inhibitors and GLP1-Receptor Agonists: Translating Evidence into Patient Outcomes

Reducing Cardiovascular Risk in T2DM with SGLT2 Inhibitors and GLP1-Receptor Agonists: Translating Evidence into Patient Outcomes

Quick Overview
Learn about evidence and techniques for using SGLT-2is and GLP-1RAs in reducing complications ...
Cart
My Cart
Availability: In stock

Price: 19.95
Required
Description

Reducing Cardiovascular Risk in T2DM with SGLT2 Inhibitors and GLP1-Receptor Agonists: Translating Evidence into Patient Outcomes

Free to AADE Members
Annual Meeting Symposium, 60 minutes
Effective dates for CE credit: 8/19/18 – 11/26/20
1.0 CE credits

Program Overview

Despite the availability of multiple therapeutic classes, the majority of conventional antidiabetic agents fail to address macrovascular risk factors and subsequent complications associated with type 2 diabetes mellitus (T2DM). As such, cardiovascular disease (CVD) remains the leading cause of death among people living with T2DM. Fortunately, emerging clinical evidence demonstrates that novel antidiabetic agents, such as sodium-glucose co-transport-2 (SGLT-2) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) not only improve glycemic control and microvascular complications but also demonstrate meaningful clinical impacts on CVD risk reduction.

Ensuring that these advances translate into real-world benefits for people with T2DM relies on the identification of people who are most likely to benefit from novel agents and their appropriate use as part of individualized treatment paradigms, the management of potential treatment-related adverse events, and importantly, the requirement of individuals to be persistent with these therapies as part of multimodal CV risk reduction strategies.

This symposium reviews the latest data on cardiovascular outcomes related to use of SGLT-2 inhibitors and GLP-1RAs, among other blood sugar lowering agents, the impact of available and emerging data on care and clinical outcomes. Importantly, this activity addresses practical diabetes educator-driven strategies to optimize the appropriate use of novel agents as part of T2DM and CVD self-management.

Activity Type:

This recording of a live presentation is a knowledge-based learning activity.

Learning Objectives

At the end of this presentation, the participant will be able to:

- Recognize the efficacy, safety, and impact of SGLT-2 inhibitors and GLP-1RAs in reducing micro- and macrovascular disease and nephropathy.
- Identify individuals living with diabetes who are likely to benefit from pharmacological agents that reduce micro- and macrovascular risk reduction as part of individualized T2DM treatment strategies.
- Propose techniques to provide specific education to individuals living with diabetes regarding the use of SGLT-2 inhibitors and GLP-1RAs as part of micro- and macrovascular risk reduction strategies.

Learning Outcome

The purpose of this activity is to enable the learner to identify and educate appropriate indivduals for effective, safe use of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing microvascular and macrovascular disease including nephropathy.

Intended Audience

This is a knowledge-based activity designed for individual or groups of diabetes educators, including RNs, RDs, Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, Physician Assistants, MDs, and other health care providers interested in staying up to date on current practices of care for their patients with diabetes and other related conditions.

Faculty

Jack Leahy, MD
Co-Chief Division of Endocrinology, Diabetes, and Metabolism
University of Vermont

Erica Hall, MSN, ANP-BC, CDE
Division of Endocrinology, Diabetes, and Metabolism
Johns Hopkins University School of Medicine

Support

This program is supported by an educational funding provided by AstraZeneca Pharmaceuticals LP.

Continuing Education Credit

This educational program will provide 1.0 contact hours of continuing education credit. To successfully complete the program to earn CE credit, learners must view the recorded session in its entirety, successfully complete short pre- and post-learning assessments, and submit an evaluation survey. A continuing education statement of credit will be provided online.

Accreditation Information

Registered Nurses

The American Association of Diabetes Educators is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This educational program will provide 1.0 contact hours of continuing education credit.

AADE is accredited as a provider of continuing nursing education by the California Board of Registered Nursing (CEP # 10977).

Registered Dietitians

The American Association of Diabetes Educators, (AM001) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.0 continuing professional education units (CPEUs) for completion of this program. Continuing Professional Education Provider Accreditation does not constitute endorsement by CDR of a provider, program, or materials.

Registered Pharmacists

The American Association of Diabetes Educators is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This program provides 1.0 contact hours (0.10 CEUs) of continuing education credit.

ACPE Universal Program Number: 0069-9999-18-129-H01-P
Effective Dates: 8/19/18 – 11/26/2020

Faculty Disclosures

It is the policy of the American Association of Diabetes Educators to require that anyone who has an opportunity to affect continuing education activities content (e.g. authors, presenters and program planners) with products or services from a commercial interest with which s/he has financial relationships, discloses those financial relationship/s with commercial entities to participants.

Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Relevant disclosures (or lack thereof) among educational activity faculty and planners are as follows.

Faculty:
- Jack L. Leahy, MD: Consultant – Janssen Pharmaceuticals Inc, Merck & Co Inc, and Novo Nordisk.
- Erica L. Hall, MSN, ANP-BC, CDE, has no relevant financial disclosures to report.

Planning Committee:
- Jodi Lavin-Tompkins, MSN, RN, CDE, BC-ADM, AADE, has no relevant financial disclosures to report.
- Joanne Rinker, MS, RD, CDE, LDN, FAADE, AADE, has no relevant financial disclosures to report.
- Adrienne Roser, ASiM, has no relevant financial disclosures to report.
- Jeffrey Stein, ASiM, has no relevant financial disclosures to report.

The approval of this educational offering by the AADE does not imply endorsement of specific therapies, treatments, or products discussed in the presentations. Any discussion of off-label use or investigational information is disclosed to the learners during the presentation.

Originally presented on: 8/19/2018
Expiration date: 11/26/2020

Access Period

You will have access to this learning activity for a period of six months after you enroll, or whenever the activity's CE credits expire (whichever comes first).

Price

Members: $0.00
Non-Members: $19.95

Volume discounts are available and will be automatically applied at check-out when the desired quantity is selected
-- Groups of 4-9: 10% off
-- Groups of 10-19: 20% off
-- Groups of 20-29: 30% off
-- Groups of 30+ and Members: Contact education@aadenet.org to get a custom quote.


We're sorry, but there is no inventory for the product you selected. Check out these other great products:

Related Items

    Products Others Bought

    • Pathophysiology Educational Tool

      Pathophysiology Educational Tool

      A teaching tool designed for for educators to explain the differences between standard, Type 1, early and late Type 2 pathophysiology. Can be used in 1:1 or group teaching sessions....

    • AADE7 Self-Care Behaviors Laminated Poster

      AADE7 Self-Care Behaviors Laminated Poster

      Single poster The AADE7 Self-Care BehaviorsTM Laminated Poster has been designed to illustrate the AADE7 Self-Care Behaviors. The poster measures 10" x 13" and can sit on a desk, be taken to progr...

    • AADE7 Goal Sheets-Spanish (Pack of 100)

      AADE7 Goal Sheets-Spanish (Pack of 100)

      3-part carbonless form...

    • AADE7 Goal Sheet-English (Pack of 25)

      AADE7 Goal Sheet-English (Pack of 25)

      Package of 25 Goal Sheets The AADE7 Self-Care BehaviorsTM Goal Sheet is a 3-part carbonless form designed to help diabetes educators introduce patients to the AADE7 Self-Care BehaviorsTM, serve as ...

    Reviews
    No records found.